title: Re: Mazarati et al. "...clinically available [antiepileptic drug] with a moderate affinity for the glycine site of the N-methyl-D-aspartate (NMDA) receptor".
authors.forename: M A
authors.initials: MA
authors.lastname: Rogawski
authors.forename: C G
authors.initials: CG
authors.lastname: Wasterlain
authors.forename: A M
authors.initials: AM
authors.lastname: Mazarati
mesh_terms: D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy; D000078328:Felbamate; D005998:Glycine / Q000378:metabolism; D006801:Humans; D016202:N-Methylaspartate / Q000378:metabolism; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000494:pharmacology* / Q000627:therapeutic use; D018009:Receptors, Glycine / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000187:drug effects*
chemical_list: D000927:Anticonvulsants; D048448:Phenylcarbamates; D011409:Propylene Glycols; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; D005998:Glycine; D000078328:Felbamate